Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Show more
21925 W. Field Parkway, Deer Park, IL, 60010-7278, United States
Market Cap
490.2M
52 Wk Range
$11.09 - $23.00
Previous Close
$18.28
Open
$18.34
Volume
427,940
Day Range
$18.04 - $18.72
Enterprise Value
536.3M
Cash
37.12M
Avg Qtr Burn
N/A
Insider Ownership
4.52%
Institutional Own.
59.73%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ZONISADE (Zonisamide) (ET-104) Details Rare genetic disease, Neurological disorder | Approved Update | |
EPRONTIA (Topiramate Oral Solution) (ET-101) Details Tonic-clonic seizures / seizures / migraine | Approved Quarterly sales | |
Carbaglu® (carglumic acid tablets) Details Hyperammonemia NAGS deficient, chronic hyperammonemia | Approved Quarterly sales | |
Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) Details Itchy Eyes Associated with Allergies | Approved Quarterly sales | |
Rezipres (Ephedrine Injection) (ET-203) Details Injectable hospital-use product | Approved Quarterly sales | |
Biorphen® (phenylephrine HCI) Details Hypotension (vasodilation in the setting of anesthesia) | Approved Quarterly sales | |
GALZIN/Zinc Acetate (Zinc Acetate) (Copper Chelator) Details Wilson Disease | Approved Quarterly sales | |
GALZIN/Zinc Acetate (Zinc Acetate) (Copper Chelator) Details Wilson Disease | Approved Quarterly sales | |
PKU GOLIKE (PKU GOLIKE) (Medical Food) Details Phenylketonuria | Approved Quarterly sales | |
Cysteine hydrochloride injection (generic - ANDA) Details Additive to amino acid solutions to meet the nutritional requirements of newborn infants | Approved Quarterly sales | |
ALKINDI® SPRINKLE (hydrocortisone) Details Adrenocortical Insufficiency (Pediatrics) | Approved Quarterly sales | |
KHINDIVI™ (hydrocortisone) Oral Solution Details Pediatric Adrenocortical Insufficiency | Approved Quarterly sales | |
Nitisinone Capsules Details Tyrosinemia type 1, Rare diseases | Approved Quarterly sales | |
Betaine Anhydrous (Betaine Anhydrous) (Methyl Donor) Details Homocystinuria | Approved Quarterly sales | |
ET-600 (Desmopressin Oral Solution) Details Diabetes insipidus | PDUFA Approval decision | |
ET-800 (Extended-Release Drug) Details Adrenal insufficiency | Phase 3 Update | |
Amglidia/Glibenclamide (Glibenclamide) (Sulfonylurea Agent) Details Neonatal Diabetes | Phase 3 Update | |
Phase 3 Update | ||
INCRELEX/Mecasermin (Mecasermin) (IGF-1 Agonist) Details Severe Primary IGF-1 Deficiency Label Expansion | Phase 1 Initiation | |
ET-700 (Extended-Release Drug) Details Undisclosed Indication | Phase 1 Initiation | |
ET-700 (Extended-Release Drug) Details Undisclosed Indication | Phase 1 Initiation | |
Dehydrated Alcohol Injection (DS-100) Details Methanol poisoning | Failed Discontinued | |
Lamotrigine Oral Suspension (ET-105) Details Seizures, Epilepsy, Lennox-Gastaut syndrome | Failed Discontinued |
